This overview groups some of the recent studies highlighting the potential application of Raman micro-spectroscopy as an analytical technique in preclinical development to predict drug mechanism of action and in clinical application as a companion diagnostic and in personalised therapy due to its capacity to predict cellular resistance and therefore to optimise chemotherapeutic treatment efficacy.
Introduction:
Vibrational spectroscopy can perform cellular imaging in a (benchtop) microscopic geometry, and can provide non invasive label free screening of, for example, nanoparticle or drug uptake, trafficking and interaction mechanisms, as well as cellular responses and toxicity [1] [2] [3] [4] [5] , eliminating the need for multiple assays in toxicological screening and drug discovery and preclinical screening stages, by elaborate robotic High Content Analysis systems. Vibrational spectroscopy has also been demonstrated for diagnostics applications, in vivo and ex vivo, in tissue [6, 7] , cells [8, 9] and body fluids [10, 11] . A further potential application which is currently attracting increasing attention is in understanding and screening cellular resistance to therapeutic treatments to guide strategies for personalised therapies [12, 13] .
Both Infrared absorption (IR) and Raman spectroscopy can be performed on live cells [14, 15] , although the significantly lower contribution of water in the latter favour it for live cell analysis [10] . Raman micro-spectroscopy also provides superior spatial resolution to IR spectroscopy, being an optically based microscopy technique, commonly employed in a confocal mode, enabling subcellular analysis of biological processes at an organelle level [15] . Raman spectral maps of whole live cells can be performed over minutes to hours, but in cases where spectral quality is favoured over speed, for detailed analysis, measurement protocols often entail fixing the cells at fixed time points after exposure to exogenous agents, for example radiation or toxicants, having optimised protocols for cell fixation [16] . Both IR and Raman spectroscopy have been used to assess the effects of drugs on cells, demonstrating their potential to measure changes in a high throughput manner and therefore can be used in drug screening [17] [18] [19] .
Many studies have reported the use of vibrational spectroscopy to monitor the effects of anticancer agents, including polyphenols [20] cardiotonic steroids [21] , and platinum compounds [22] , on cancer cells, and Hughes et al. [17] , Mignolet et al. [23] and Jamieson and Byrne [24] have recently reviewed the potential for vibrational micro-spectroscopy as a label free in vitro platform for screening the mechanisms of action and efficacies of candidate drugs at the discovery and pre-clinical screening stages. The development of such in vitro screening techniques is particularly pertinent at present, given the increasing legislative pressure to develop in vitro alternatives to animal models for scientific research and product development as prioritised by the EU Directive-2010/63/EU on the replacement, reduction and refinement of animal experimentation.
Using Fourier Transform IR (FTIR) microscopy, Derenne et al. demonstrated that drugs of similar mode of action have similar spectroscopic signatures [19] , indicating potential applications in pre-clinical screening of the mode of action of new candidate drugs. Analysis of spectral variations in prostate cell lines, induced by drug exposure, clustered drugs classified as anti-microtubules (methotrexate, mercaptopurine), anti-topoisomerases (vincristine, vinblastine, paclitaxel) and anti-metabolites (doxorubicin, daunorubicin) separately. Derenne et al. further demonstrated that the spectral changes were not cell line specific, but were consistent over seven different cell lines [25] . Mignolet et al. [23] reviewed the body of work exploring IR signatures of anti-cancer drugs inside cancer cells and changes induced after drug exposure, including the effects of cell cycle and cell culture model, arguing that FTIR can be employed for screening of new drug candidate molecules for known or unknown modes of action.
Using Raman spectroscopy, subcellular resolution can be achieved due to the high spatial resolution achievable with optical microscopy, allowing intracellular organelles to be resolved.
Raman spectra are also typically recorded at higher spectral resolution than IR spectra, and therefore more detailed biochemical information can be gained [26] , with more potential for elucidating 'modes of action' by analysis of the detailed spectral changes. El-Mashtoly et al. [27] demonstrated the capability of Raman spectroscopy for monitoring the distribution of the distinct structure of erlotinib, containing a carbon-carbon triple bond, and its metabolic products in colorectal adenocarcinoma SW480 cells. Le Roux et al. [28] explored cell death routes after exposure to gold based metallodrugs. Salehi et al. [29, 30] and Feofanov et al. [31] probed the resonance Raman response to detect and study cellular responses after exposure to paclitaxel, and the nonfluorescent transition-metal complex, Theraphtal, respectivelly. Draux et al. [32] investigated the effect of Gemcitabine on cell biomolecules in the lung cancer cell line Calu-1, after 48hrs exposure. Moritz et al. [33] used laser tweezers Raman spectroscopy to study the effects of doxorubicin on leukaemia cells and demonstrated that drug exposed cells exhibited an increase in DNA features after prolonged exposure time. Schie et al. [34] also investigated the effect of doxorubicin on malignant lymphocytes at late stages, from 24 to 96 hrs, while Guo et al. [35] explored the effects of doxorubicin on malignant hepatocytes after 12 hrs exposure, showing a decrease in DNA features and an increase in proteins and lipids features. Hartmann et al. [36] studied the effect of Docetaxel on human breast adenocarcinoma cell line MCF-7 comparing the treated cells with the untreated ones and investigating the cellular morphological changes induced by the chemotherapeutic drug. Lin et al. [37] used Raman spectroscopy to assess the cytotoxicity of Paclitaxel in CA46, human Burkitt's lymphoma cells. Zoladek et al. [38] showed the potential of Raman micro-spectroscopy for label free time course imaging (at 2 hrs intervals over 6 hrs) of live human breast cancer cell (MDA-MB-231) undergoing apoptosis after exposure to etoposide.
In monitoring the response to exogenous agents in vitro, it has also been demonstrated that both FTIR and Raman spectroscopy can potentially be employed to understand cellular resistance pathways in different cell lines. Cellular resistance pathways were specifically targeted by Yosef et al. [39] who used Raman spectral imaging to investigate the oncogenic mutation resistance to epidermal growth factor receptor targeting therapy and colon cancer cells with and without oncogenic mutations such as KRAS and BRAF mutations were treated with erlotinib , an inhibitor of epidermal growth factor receptor, in order to detect the impact of these mutations on Raman spectra of the cells as markers of cell resistance. Rutter et al. [40] utilised a cell cloning technique to specifically isolate sensitive and resistant cells from a mixed cell population, and investigated the difference in response of gemcitabine-sensitive and gemcitabine-resistant Calu-1 epidermoid lung cancer cells to the commercial drug, using IR spectroscopy. Furthermore, Siddique et al. [41] showed that it was also possible to identify differences of nilotinib-sensitive and nilotinib-resistant K562 (a chronic myelogenous leukaemia cell line) cloned cells, using both FTIR and Raman microspectroscopies. The ability of vibrational spectroscopy to characterise and differentiate responses of resistant and sensitive cell types to drugs opens up potential clinical applications as a Companion Diagnostics (CD) tool, and ultimately personalised medicine approaches [42, 43] Although the potential of in vitro spectroscopic screening of cellular processes has been well demonstrated, research has been somewhat fragmented, lacking in coherence and standardisation of measurement protocols. Critically, the analysis and interpretation of the spectral responses remains a challenge, even in the hands of "specialists". At the recent Faraday Discussions [44] , the question as to what extent individual spectral features can be assigned to specific molecular responses, given the complex nature of the samples under investigation, featured highly. By their very nature, label free techniques register all species within the sampling area, and identification of specific responses requires more sophisticated techniques to data-mine the differential responses due to cell injury or change. Regression and correlation approaches can be employed to extract the specific spectroscopic signatures of cellular changes which are correlated with external stimuli, and, for example independently elucidate the spectroscopic signatures of the direct chemical effects of the stimulus from the subsequent cellular metabolic responses. In the case of chemotherapeutic agents, the uptake, distribution and accumulation, chemical interactions and subsequent cellular metabolic responses can be monitored [17, 18] . Nevertheless, these differential spectral responses remain multivariate in nature, and contain contributions of the multitude of biochemical constituents involved. The conditioned thinking, based on a labelled approach, is to search for specific "Biomarkers". However, it is becoming increasingly apparent that the spectral response can have (additive) contributions of increased or decreased concentrations of constituent biomolecules, but also more complex contributions due to conformational, environmental (pH etc.) changes, and that identification of the (differential) spectroscopic signature, rather than specific bands associated with specific biomolecules, may be more appropriate. For realistic applications potential, however, it is important that these combinatorial signatures are characteristic of the cellular 
Cytotoxicity assays and their limits
A range of cytotoxicological assays are commonly employed to measure the in vitro responses of cell populations, including cell proliferation, viability and toxicity, after exposure to external agents such drugs, nanoparticles or radiation. Amongst these are the tetrazolium bromide (MTT), Alamar Blue (AB) and Neutral Red (NR) assays, each of which targets different aspects of the response pathway.
NR is a fluorometric dye, which measures the lysosomal activity using 3-Trimethyl-2,8phenazinediamine, monohydrochloride, which binds to the lysosomes of viable cells after penetration by passive diffusion due to its cationic charge. This uptake depends on the ability of the cell to maintain a pH gradient by production of ATP. Therefore, the dye cannot penetrate inside dead cells and the amount of retained dye is proportional to the number of viable cells. [45, 46] The MTT test is a colorimetric assay that measures the reduction of yellow 3-(4, 5dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) by mitochondrial succinate dehydrogenase into purple formazan crystals, insoluble in aqueous solution [47, 48] . Succinate dehydrogenase or succinate-coenzyme Q reductase (SQR) or respiratory Complex II is an enzyme complex, bound to the inner mitochondrial membrane of mammalian mitochondria and many bacterial cells. It is the only enzyme that participates in both the citric acid cycle and the electron transport chain, so the MTT assay is the reflection of mitochondrial activity.
Alamar blue (AB), on the other hand, is a water-soluble dye and one of the most highly used cytotoxicity assays for in vitro quantification of the cell viability [49] .When added to cell cultures, the active dye, resazurin or 7-hydroxy-10-oxidophenoxazin-10-ium-3-one, diffuses into the cytosol and acts as an intermediate electron acceptor allowing the oxidised blue nonfluorescent form to be reduced by both mitochondrial and cytosolic enzyme activity to the fluorescent pink form which is easily measured by its absorption or fluorescence. [47] [48] [49] Both AB and NR are considered an expression of general cellular metabolism and, while reduced conversion compared to controls is used as a measure of reduced cellular viability for both AB and MTT assays, the MTT response is more specifically sensitive to mitochondrial enzymes while AB is related to both mitochondrial and cytosolic activities.
Quantitatively, the cytotoxic response is commonly quoted in terms of the effective concentration with elicits 50% of the maximum response of the cell population to the exogenous agent (IC50), determined through dose-response curves. However, toxicity studies are commonly conducted at different time points, using different cell lines, leading to a lack of consistency in toxicological data for chemotherapeutic agents. Figure 1 shows, for example the accumulated cytotoxicity data as measured using the MTT assay, for Cisp [18] and Vinc [50] in A549, human lung adenocarcinoma cells, and DOX [51] and ACT [52] in both A549 and Calu 1, a human lung epidermoid carcinoma cell line, at differing time points. The inverse IC50, as a comparative measure of the toxicity [53] , is plotted against the exposure time. For the case of DOX, the toxicity increases monotonically as a function of exposure time. The two cell lines show comparable results, although that of A549 seems to saturate at prolonged exposures. In the case of ACT, although negligible response was observed at 24hrs (IC50>50M), the toxicity at 48 hrs and 72 hrs far exceeds that of DOX, in both cell lines [52] . Cisp also requires a more prolonged exposure time to elicit appreciable responses in A549 [50] , while, for the same exposure time, Vinc requires substantially lower concentration to elicit the same toxic response [50] . Maher et al. [45] developed a numerical model to simulate nanoparticle uptake, cytotoxicity and subsequent cellular response and highlighted the fact that differences in the quantitative responses of cytotoxicity assays can arise due to the fact that each assay measures different underlying cellular responses which can occur at different rates. An assessment of the action and efficacy of, for example a chemotherapeutic agent, according to a single endpoint is therefore extremely limited. Computational Modelling approaches to predictive toxicity, such as that of Adverse outcome pathways [54] , have sought to deconvolute the action of exogenous agents, in terms of the molecular initiating event (MIE) and the subsequent cascade of key events (KE) that reflect the causal progression from the initial perturbation of the system towards the adverse outcome. In the context of the action of chemotherapeutic drugs in vitro, the MIE can be considered the chemical interaction of the drug, for example in the cell nucleus, while the subsequent cascade of events can determine the efficacy of a drug action.
Understanding of the chemistry of the MIE can be key to establishing quantitative structure activity relationships to guide synthetic strategies, while understanding the subsequent pathways may be key to understanding mechanisms of drug resistance and sensitivity in different cell lines and ultimately patients. Therefore, to have a global idea of the effects of external agents such as drugs or nanoparticles on cells and identify any subsequent cellular responses, there is a need for a more developed label free method which gives a holistic picture of the cascade of events which occurs after cell exposure.
Data processing: pre and post processing
To consider vibrational spectroscopy and specifically Raman micro-spectroscopy as an analytical tool for clinical applications, it should be able to address the many challenges related to the complexity of biological samples and their chemical and physical heterogeneity. In this context, data pre and post processing play an important role in dealing with variations in instrumental responses, between different biological samples and improving spectral quality.
Byrne et al. [55] summarised the pre-processing steps routinely used to improve recorded spectra quality, and the commonly used post-processing techniques for the classification, discrimination and analysis of data set from biological samples. In fact, many factors, including background coming from sample scattering and/or fluorescence, substrate contributions, specifically when analysing thin samples, and instrumental enhanced scattering contributions, can influence spectra quality and therefore need to be subtracted. In some cases, those factors can be minimised experimentally, for example analysing samples in immersion to reduce laser scattering [6] or use of substrates with negligible Raman scattering [56] . In others cases, there is a need for pre-processing algorithms for background subtraction prior to analysis, using for example a NCLS (non-negatively constrained least squares) [57] or EMSC (extended multiplicative signal correction) algorithm [58] . Spectra are also commonly smoothed to reduce noise using the Savitsky-Golay algorithm or singular value decomposition (SVD) [59] , baseline corrected (fifth order polynomial) and vector or area normalised.
After pre-processing, data post-processing or data mining is necessary to detect and analyse changes in spectral profiles associated, for example, with biological process, drug, nanoparticle, radiation exposure etc., mostly in a large and complex data set. The most common method in terms of multivariate spectral data analysis is Principal Components Analysis (PCA), a powerful unsupervised approach for the analysis of large multidimensional data sets, which allows the reduction of the number of variables, although retaining most of the variation within the dataset. It represents the spectra in data groupings of similar variability, allowing the identification and differentiation of different spectral subgroups. The loadings of the PCs represent the variance for each variable (wavenumber) for a given PC, the order of the PCs denoting their importance to the dataset. PC1 describes the highest amount of variation, and analysis of the loadings can give information about the source of the variability inside a dataset, derived from variations in the molecular components contributing to the spectra.
It has been demonstrated that the PC loadings can be most simply understood when analysis of data subgroups is undertaken in a pairwise fashion [60, 61] , whereby the loading of the PC can be interpreted as differences of the biochemical content of the two differentiated datasets [60] , highlighting its ability to provide molecular information and biochemical differences of analysed samples. Notably, PCA does not cluster the data, per se, in the same manner as for example Hierarchical or K-Means Cluster Analysis, whereby differential distribution of the data according to negative or positive loadings associates specific spectral features with that dataset.
As an extension to PCA, independent components analysis (ICA) can also be employed as an unsupervised statistical technique to identify latent variables, called independent components, in each data set separately. In the case of Raman micro-spectroscopy, ICA can be used to identify spectral contributions such as those from substrate, which can then be removed or plotted and studied in their own [61, 62] .
More sophisticated spectral analysis is required to extract specific information related to an external variable such as exogenous exposure dose or time, requiring supervised methods such Partial Least Squared Regression (PLSR). PLSR is a statistical regression technique which reduces the dimensionality of the data and correlates information, here represented by the spectra data set, to, for example, time evolution or drug concentrations or to a gold standard assay, to track the dependent evolution of the spectral signatures in, for example, subcellular regions. The regression coefficients obtained by PLSR can be analysed and provide information about the contribution of spectral variations. As a function of frequency, the coefficients illustrate the spectral features which are influenced by the external factor selected [63] .
Raman micro-spectroscopy for chemotherapeutic pre-clinical screening
Raman spectroscopic analysis of drug-cell interactions has focused both on changes in the cellular Raman spectra upon drug application, and also during intracellular tracking of the drug and its metabolites. [1, 27, 51, 52, 64] Farhane et al. [1, 51, 61, 63] used Raman spectroscopy to determine not only the subcellular location of the drug DOX in A549 and Calu-1 human lung adenocarcinoma cells, but also the differing pharmacodynamics of the drug uptake and subcellular localization, as well as the subsequent cellular responses, over a period 0-72hrs. In fact, using Raman micro-spectroscopy, DOX could be clearly detected in both the nucleolus and surrounding nucleus, while Confocal Laser Scanning Microscopy (CLSM) images show that only the nucleus appears red (compared to the corresponding controls, in which no fluorescence is detected), due to the characteristic DOX fluorescence (Figure 2 ), the clearly visible dark spots of the nucleoli suggesting that DOX does not accumulate in the nucleoli. However, Raman micro-spectroscopy clearly demonstrates that DOX does accumulate in the nucleoli, indicating that the dark spots are a result of fluorescence quenching in the environment. The study also indicated that DOX selectively targets the RNA in the nucleolus, before the nuclear and cytoplasmic regions. Using multivariate data analysis, consisting of PCA, ICA and PLSR, Raman microspectroscopy was shown to be capable of tracking the kinetics of the uptake and accumulation of DOX at a subcellular level in vitro [51, 63] . Results show that the chemotherapeutic drug accumulates first in, and saturates, the nucleolus, then the nucleus and is only detectable in the cytoplasm at later stages, after nuclear disruption ( Figure 3A) . (Figure 4 ). The substantially slower uptake rate for ACT (48- 72hrs) compared to DOX (6-12hrs) may be due to different side chain composition.
Nevertheless, both exploit similar cellular pathways, accumulating first in the nucleolus and then the nucleus, which suggests that the anthracycline chemotherapeutic group targets the nucleolus first, binding with RNA, and nucleus second, binding with DNA, before accumulating in the cytoplasm. This is not the accepted view of the mode of action of anthracycline drugs, which considers only the interaction with nuclear DNA and parallel interactions in the cytoplasm [65] [66] [67] , and so, in both cases, Raman micro-spectroscopy has shed further light on the current understanding of the mode of action of the clinically prescribed chemotherapeutic agents.
A.
B.
Figure 4:
Loading 1 of PC1 of control versus exposed cells of Nucleolus A. A549 control versus 6hrs DOX exposure compared to that of control versus 48hrs exposure ACT B. Calu-1 control versus 2hrs DOX exposure compared to that of control versus 48hrs exposure ACT Nawaz et al. [18, 68] Cisp binding [18, 71, 72] .
In acellular circular dichroism studies of drug DNA interactions, the spectral changes observed for the ACT-DNA complexes due to a B to A-type DNA transition upon interaction, are distinct from those of Cisp-DNA complexes, which reflect distortions in DNA of a nondenaturational nature [73] . Therefore, it is not expected that Cisp will induce similar conformational changes to DOX or ACT.
A.
B. In a similar, more recent, study of the effects of Vinc, Raman spectroscopy demonstrated that, as well as the accepted mechanism of action of microtubule binding, intercalation with nuclear DNA occurs at high doses [50] . Using Flow Cytometry to measure the anti-apoptotic bcl-2 protein expression reveals that it depends on the Vinc concentration; at low concentration, the bcl-2 protein expression increases, inhibiting cell death by apoptosis and drops at higher concentrations due to higher levels of DNA damage. This is confirmed by a PLSR regression of the spectral responses of the nucleus versus Vinc dose at low and high doses, as shown in Figure 5B . At low doses (<IC50), a single negative feature is observed at 795 cm -1 , whereas regression over the doses above the IC50 results in the double feature at 785 cm -1 and 810 cm -1 , characteristic of DNA intercalation and resultant conformational changes.
The studies of Cisp and Vinc demonstrate that a drug can have different modes of action, dependent on dose, [18, 50, 74, 75] , and, indeed this is also demonstrated by the time evolution Despite the fact that those three chemotherapeutic drugs belong to different classes, they present a common mechanism of action by interaction with nucleic acids manifest in Raman analysis by the simultaneous decrease of features at 785 and 813 cm −1 . This can therefore be considered as a marker and a fingerprint of DNA intercalation and can be explored for new chemotherapeutic candidates. A similar decrease in features at 728 (adenine), 1095 (DNA PO2− symmetric stretching), 1376 (thymine), 1486 and 1577 cm −1 (adenine and guanine) is also observed for the three drugs, indicating that they can interact with the four nucleic bases and bind externally with DNA.
The identification of such common spectroscopic signatures associated with a mode of action of these chemotherapeutic agents or cellular reactions can potentially be exploited for preclinical screening of the mode of action and potential resistance of new candidate chemotherapeutic agents.
Besides similar nucleic acids features, notable increases in protein features at 645 and 877 cm −1 , related to tyrosine, and 115-1130 cm −1 , related to C-N protein stretching, and lipids at 700 cm −1 , are also observed for the three drugs, which may be indicative of changes in protein structure and cellular resistance by synthesis of anti-apoptotic proteins and lipidic vesicules, as a way to remove DOX to the extracellular environment and thus could be considered as a marker of possible chemotherapeutic failure.
Raman micro-spectroscopy to distinguish cellular resistance
Farhane et al. [51] , in a comparative study between the two lung cancer cell lines A549 and
Calu-1 exposed to DOX at the dose corresponding to the IC50 of each, demonstrated that, despite the fact that there is a much faster uptake of DOX and cellular saturation in Calu-1 cells ( Figure 3A and Figure 7B ), they are more resistant than A549 cells and exhibit earlier evidence of a secondary mechanism of action of DOX, by ROS production [61] . In fact, Raman investigations show that the accumulation of DOX in the cytoplasmic area happens due to nuclear disruption, and as a consequence, the ROS production starts only after nuclear saturation, and that the two mechanisms of action, nucleic acid intercalation and ROS production, do not happen simultaneously. Further investigations demonstrate that, for both cells lines, there is a decrease in cellular features concomitant with DOX saturation, Calu-1 cells exhibiting higher DNA damage. However at later stages ( Figure 3B and Figure 7B ) in Calu-1 cells, there is a recovery of DNA and protein features, which suggests the intervention of DNA repair mechanisms and synthesis of anti-apoptotic proteins (confirmed by measurement of bcl-2, an anti-apoptotic protein and γH2AX, a marker of DNA damage and repair), both considered as mechanisms of cellular resistance. In fact, as seen in Figure 6 for A549 cells, there is an increase in γH2AX up to 24hrs corresponding to an increase in DNA damage and the increase in Bcl-2 protein is only up to 12hrs, with a continuous decrease in DNA, suggesting failure in anti-apoptosis and DNA recovery mechanisms. However, in Calu-1 cells, the bcl-2 expression continues to increase until the later stage of 48hrs, a decrease in γH2AX starting at 12hrs and a DNA recovery at late stages, consistent with a higher resistance than A549 cells (Figure 7) .
A.
B. A similar study by Farhane et al. [52] , using ACT, also demonstrates the difference in chemosensitivity between A549 and Calu-1 cells. A higher viability and larger increase in protein features was observed in A549 cells, despite the fact that the two cell subtypes present similar ACT uptake rates.
The cell/drugs interaction induces different cellular reactions in the two cell lines, Calu-1
showing higher resistance for DOX and higher sensitivity for ACT. This difference in cellular reactions between cell lines and between the anthracyclines, as observed in protein features corresponding to synthesis of anti-apoptotic proteins and mobilisation of DNA repair proteins, may be due to differential drug retention rather than drug uptake, as ACT uptake is similar for the two cell lines and DOX uptake is faster in Calu-1 than A549 (which suggest higher sensitivity of Calu-1 to DOX than A549 and not the opposite).
The ability of Raman micro-spectroscopy to characterise and differentiate responses of resistant and sensitive cell types to drugs opens up potential clinical applications as a Companion Diagnostics tool, and ultimately personalised medicine approaches as a predictive tool for patient responses in individualised treatment.
Discussion:
Cytotoxicity assays are routinely employed to monitor the cellular viability and toxicity to external treatment individually or in a high content format. However, they give a limited insight into the mode of action and efficacy of drugs. In this context, Raman micro-spectroscopy can provide a label free alternative to high content analysis, potentially in real-time analysis with subcellular resolution and more profound understanding of mechanism of action of drugs and the subsequent cellular response pathways.
In the case of DOX, the IC50 concentration is high enough that it makes it possible to detect it inside cells and to monitor its uptake and accumulation at a subcellular level using Raman The consistency of the spectroscopic signatures for drugs of similar modes of action, in different cell lines, suggests that this fingerprint can be considered a "spectralome" of the drugcell interaction suggesting a new paradigm of representing spectroscopic responses. Notably, although the signature can contain features which can be associated with specific biomolecules, such as RNA, the full spectrum of that biomolecule is not manifest in the "spectralome", indicating that the spectral contributions can arise from conformational or other changes associated with the local environment of the biomolecule, and the "spectralome" also contains contributions of other molecules within that environment. In the absence of a labelling strategy, what you see is what you get, but the "spectralome", is a more holistic view of the biochemical changes associated with the drug-cell intereaction.
The ability of Raman micro-spectroscopy to characterise and differentiate responses of resistant and sensitive cell types to drugs opens up potential clinical applications as a Companion Diagnostics (CD) tool, and ultimately personalised medicine approaches [13, 42, 43] . The US Food and Drug Administration (FDA) defines CD as "a medical device, often an in vitro device (IVD), which provides information that is essential for the safe and effective use of a corresponding drug or biological product". Ultimately, the IVD should screen for patient specific suitability of therapeutic treatments, and both the FDA and the European Medicines Agency (EMA) now actively encourage the use of CD in the development and use of prescription drugs and even require CD marker testing prior to the prescription of certain drugs. Although more complex genomics based tests are emerging, most currently employed CD techniques are based on individual biomarkers in tissue or serum and, as is the case for fluorescent labels in microscopy, provide an extremely limited picture of the action of the drug and the cellular response. Emerging, more rapid spectroscopic screening technologies will afford more continuous and even real-time monitoring of such intracellular processes and response pathways, which ultimately may be analysed using more sophisticated data mining techniques such as Multivariate Curve Resolution Alternating Least Squares. It can be projected, therefore, that Raman micro-spectroscopy can potentially contribute significantly to this field, by screening responses to identified therapeutics in patient derived cells, label-free, identifying signatures of cell resistance/sensitivity.
Conclusion:
The potential of Raman micro-spectroscopy not only to track in vitro the kinetics and accumulation of chemotherapeutic drugs at a subcellular level but also to identify their different mechanisms of action, for example via DNA intercalation and ROS production, according to different time points and doses and to identify factors contributing to chemotherapeutic resistance has been demonstrated.
In fact, Raman investigations show that drugs with similar mechanism of action, for example DNA intercalation, exhibit the same spectral signatures, which can be considered as a molecular fingerprint of their cellular interaction, opening the way to a new paradigm of in vitro analysis and characterisation, spectralomics. There is a dearth of techniques to visualise the action of drugs in situ in cells, and thus, Raman micro-spectroscopy can be used as an in vitro guide to medicinal chemistry strategies and a pre-clinical screening technique for drug mechanism of action and efficacy in order to aid preclinical drug development. Furthermore, the ability of Raman micro-spectroscopy to monitor subcellular processes associated with drug resistances suggests its potential as an in vitro companion diagnostics technique to screen for personalised therapies.
